title: Proapoptotic ginsenosides compound K and Rh enhance Fas-induced cell death of human astrocytoma cells through distinct apoptotic signaling pathways.
abstract: OBJECTIVE
  Malignant astrocytomas are among the commonest primary brain tumors and they have a grave prognosis, and so there is an urgent need to develop effective treatment. In this study, we investigated the molecular mechanisms that are responsible for the anti-tumor effect of ginsenosides on human astrocytoma cells.
  
  
  METHODS
  We tested 13 different ginsenosides for their anti-tumor effect on human malignant astrocytoma cells in conjunction with Fas stimulation. In addition, the cell signaling pathways were explored by using pharmacological inhibitors and performing immunoblot analysis. DCF-DA staining and antioxidant experiments were performed to investigate the role of reactive oxygen species as one of the apoptosis-inducing mechanisms.
  
  
  RESULTS
  Among the 13 different ginsenoside metabolites, compound K and Rh(2) induced apoptotic cell death of the astrocytoma cells in a caspase- and p38 MAPK-dependent manner, yet the same treatment had no cytotoxic effect on the primary cultured human astrocytes. Combined treatment with ginsenosides and Fas ligand showed a synergistic cytotoxic effect, which was mediated by the reduction of intracellular reactive oxygen species.
  
  
  CONCLUSIONS
  These results suggest that ginsenoside metabolites in combination with Fas ligand may provide a new strategy to treat malignant astrocytomas, which are tumors that are quite resistant to conventional anti-cancer treatment.
authors.affiliation: Laboratory of Computational Cell Biology, Department of Bio and Brain Engineering, KAIST, Daejeon, Korea.
authors.forename: Kyungsun
authors.initials: K
authors.lastname: Choi
authors.forename: Chulhee
authors.initials: C
authors.lastname: Choi
references.citation: Blood. 2003 Jul 1;102(1):336-43
references.pmid: 12623840
references.citation: Liver Int. 2005 Oct;25(5):1069-73
references.pmid: 16162168
references.citation: J Korean Med Sci. 2001 Dec;16 Suppl:S38-41
references.pmid: 11748375
references.citation: Free Radic Biol Med. 2003 Sep 15;35(6):648-61
references.pmid: 12957657
references.citation: Toxicol Sci. 2006 Jun;91(2):356-64
references.pmid: 16547074
references.citation: J Immunol. 1999 Feb 15;162(4):1889-95
references.pmid: 9973455
references.citation: Cell Biol Int. 2007 Sep;31(9):1027-35
references.pmid: 17468017
references.citation: Brain Res Brain Res Rev. 2004 Jan;44(1):65-81
references.pmid: 14739003
references.citation: Neurosci Lett. 2007 Jun 21;421(1):37-41
references.pmid: 17548155
references.citation: Cancer Lett. 2004 Mar 8;205(1):23-9
references.pmid: 15036657
references.citation: Mol Cell Biol. 2002 Feb;22(3):724-36
references.pmid: 11784850
references.citation: Biochem Int. 1992 Jul;27(3):501-10
references.pmid: 1417886
references.citation: Science. 1995 Mar 10;267(5203):1449-56
references.pmid: 7533326
references.citation: Mol Cancer Ther. 2007 Jul;6(7):1909-19
references.pmid: 17620423
references.citation: EMBO J. 1996 Jan 15;15(2):216-25
references.pmid: 8617197
references.citation: J Neurooncol. 2004 Mar-Apr;67(1-2):167-76
references.pmid: 15072464
references.citation: Science. 2006 Jun 30;312(5782):1882-3
references.pmid: 16809515
references.citation: Brain Res. 2007 Mar 9;1136(1):190-9
references.pmid: 17239831
references.citation: Mol Carcinog. 2004 Jan;39(1):1-9
references.pmid: 14694442
references.citation: EMBO J. 1998 Mar 16;17(6):1675-87
references.pmid: 9501089
references.citation: J Biol Chem. 2002 Jun 14;277(24):21446-52
references.pmid: 11934900
references.citation: Planta Med. 2006 Jun;72(7):627-33
references.pmid: 16673329
references.citation: Cancer Lett. 2007 Nov 8;257(1):79-86
references.pmid: 17692455
references.citation: Oncogene. 2007 May 14;26(22):3100-12
references.pmid: 17496909